Alaina Lurie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alaina Lurie has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Rossi
Icahn School of Medicine at Mount Sinai, New York, NY
10 shared publications - Ajai Chari
Department of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA
10 shared publications - Alex Lieberman-Cribbin
Icahn School of Medicine at Mount Sinai, New York, USA
10 shared publications - Cesar Rodriguez
Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
10 shared publications - Guido Lancman
Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON
10 shared publications - Hearn Jay Cho
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
10 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Absolute neutrophil counts over time in individual patients
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Absolute neutrophil counts over time in individual patients
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Anonymized patient-level data. Drug names have been de-identified and will be made available upon request once all of the sponsors have published results from these trials.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Anonymized patient-level data. Drug names have been de-identified and will be made available upon request once all of the sponsors have published results from these trials.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for bacterial grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for bacterial grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Absolute lymphocyte counts over time in individual patients
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Absolute lymphocyte counts over time in individual patients
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Supplementary Table S1: Description of all grade 3-5 infections. Supplementary Table S2: Infection rates per time period from start of bispecific antibody, divided by presumed microbiology. Rates are presented as infections per patient-year (95% confidence intervals). Supplementary table S3: Univariate logistic regression analysis of baseline risk factors for grade 3-5 infections among responders.
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Supplementary Table S1: Description of all grade 3-5 infections. Supplementary Table S2: Infection rates per time period from start of bispecific antibody, divided by presumed microbiology. Rates are presented as infections per patient-year (95% confidence intervals). Supplementary table S3: Univariate logistic regression analysis of baseline risk factors for grade 3-5 infections among responders.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for all grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for all grade 1-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for bacterial grade 3-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Swimmer’s plot for bacterial grade 3-5 infections during the study period, divided into ‘On-IVIg’ and “Off-IVIg’ periods
- Open Access
- 1 July 2025
- Published by SAGE Publications in Advances in Methods and Practices in Psychological Science
- Vol. 8 (3)
A Window Into the State of the Science: Current Reporting Practices Related to Generalizability in MRI and Functional-MRI Studies
Concerns for the replicability, reliability, and generalizability of MRI and functional MRI (fMRI) research have led to debates over the contributions of sample size, open-science practices, and recruitment methods, particularly in the psychological sciences. Key to understanding the state of a science is an assessment of reporting practices. In this structured review, we evaluated select reporting practices across three domains: (a) demographic (e.g., age), (b) methodological (e.g., inclusion/exclusion criteria), and (c) open science and generalizability (e.g., preregistration, target-population identification). Included were 919 published MRI and fMRI studies from 2019 in nine top-ranked journals. Reporting across domains was infrequent; participant racial-ethnic identity (14.8%), reasons for missing imaging data (31.2%), and identification of a target population (19.4%) were particularly low. Reporting likelihood varied by study characteristics (e.g., journal) and was correlated across domains. Finally, study sample size but not reporting frequency was positively associated with 2-year citation counts. Results call for recentering transparency in reporting practices in MRI and fMRI studies, with direct implications for study generalizability.
- 1 July 2025
- Published by SAGE Publications in Advances in Methods and Practices in Psychological Science
- Vol. 8 (3)
Open AccessA Window Into the State of the Science: Current Reporting Practices Related to Generalizability in MRI and Functional-MRI Studies
Concerns for the replicability, reliability, and generalizability of MRI and functional MRI (fMRI) research have led to debates over the contributions of sample size, open-science practices, and recruitment methods, particularly in the psychological sciences. Key to understanding the state of a science is an assessment of reporting practices. In this structured review, we evaluated select reporting practices across three domains: (a) demographic (e.g., age), (b) methodological (e.g., inclusion/exclusion criteria), and (c) open science and generalizability (e.g., preregistration, target-population identification). Included were 919 published MRI and fMRI studies from 2019 in nine top-ranked journals. Reporting across domains was infrequent; participant racial-ethnic identity (14.8%), reasons for missing imaging data (31.2%), and identification of a target population (19.4%) were particularly low. Reporting likelihood varied by study characteristics (e.g., journal) and was correlated across domains. Finally, study sample size but not reporting frequency was positively associated with 2-year citation counts. Results call for recentering transparency in reporting practices in MRI and fMRI studies, with direct implications for study generalizability.
- Open Access
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.Significance:To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.See related commentary by Garfall and Stadtmauer, p. 427.This article is featured in Selected Articles from This Issue, p. 419
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.Significance:To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.See related commentary by Garfall and Stadtmauer, p. 427.This article is featured in Selected Articles from This Issue, p. 419
- Open Access
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.Significance:To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.See related commentary by Garfall and Stadtmauer, p. 427.This article is featured in Selected Articles from This Issue, p. 419
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.Significance:To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.See related commentary by Garfall and Stadtmauer, p. 427.This article is featured in Selected Articles from This Issue, p. 419